Use of stents in the carotid artery is just the latest migration of stent technology from the coronary artery to important arteries outside or "peripheral" to the heart, said Howard Rosen, director of the carotid endovascular program at Boston Scientific Corp.Rosen estimated that the overall market for stents in neck arteries eventually might reach $1 billion in value, although current sales are much lower.
Quoting Howard Rosen of Boston Scientific, the article states that Medicare covers just 5% to 7% of beneficiaries with carotid artery disease, and that the expanded coverage would include between 15% and 20% of beneficiaries.
Under current policy, Medicare covers the new procedure for between 5% and 7% of beneficiaries with carotid artery disease, and the expansion under consideration by CMS would increase the rate to between 15% and 20%, according to Howard Rosen, director of the carotid endovascular program at Boston Scientific.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.